A61K 40/4275
Prostate specific antigen [psa]
Official title: {Prostate specific antigen [PSA]}
A61K40/4275 (Prostate specific antigen [psa]) appears on 49 US grants and 101 published applications in this corpus.
Search patents in A61K- Granted patents
- 49
- Published applications
- 101
- Assignees
- 45
- Inventors
- 172
- Latest grant
- 25 Feb 2025
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2001 | 1 | 0 |
| 2002 | 0 | 9 |
| 2003 | 0 | 6 |
| 2004 | 2 | 5 |
| 2005 | 2 | 3 |
| 2006 | 5 | 4 |
| 2007 | 1 | 2 |
| 2008 | 0 | 9 |
| 2009 | 1 | 2 |
| 2010 | 1 | 4 |
| 2011 | 2 | 6 |
| 2012 | 3 | 4 |
| 2013 | 2 | 5 |
| 2014 | 3 | 3 |
| 2015 | 2 | 8 |
| 2016 | 2 | 1 |
| 2017 | 4 | 4 |
| 2018 | 4 | 5 |
| 2019 | 1 | 6 |
| 2020 | 5 | 4 |
| 2021 | 3 | 5 |
| 2022 | 3 | 0 |
| 2023 | 0 | 3 |
| 2024 | 1 | 2 |
| 2025 | 1 | 1 |
By publication year.
Recent patents
- Chimeric transmembrane protein comprising antibody dimerization domains and a type I cytokine receptor endodomain, encoding nucleic acids thereof and methods of use thereof25 Feb 2025US 12,234,295 B2Autolus Limited
- Compositions and methods for modified b cells expressing reassigned biological agents28 May 2024US 11,993,646 B2Kota Biotherapeutics, LLC
- Methods for treating cancer or modulating T cells or NK cells in a subject by administering cells comprising chimeric transmembrane proteins25 Oct 2022US 11,479,613 B2Autolus Limited
- Methods for treating cancer or modulating T cells or NK cells in a subject with cancer by administering cells comprising chimeric cytokine receptors25 Oct 2022US 11,479,614 B2Autolus Limited
- Cell21 Jun 2022US 11,365,262 B2Autolus Limited
- Chimeric cytokine receptor30 Oct 2025US 2025/0333538 A1Autolus Limited
- Cellular therapies for cancer by inhibition of monocarboxylate transporter 113 Oct 2024US 2024/0325537 A1University of Pittsburgh—Of the Commonwealth System of Higher Education
- Compositions and methods to reduce therapeutic t cell toxicity2 May 2024US 2024/0139322 A1H. Lee Moffitt Cancer Center and Research Institute, Inc.
- Methods and Compositions Comprising Orthogonal Cytokine Responsive Immune Cells16 Nov 2023US 2023/0364238 A1The Board of Trustees of the Leland Stanford Junior University
- T cells and chimeric stimulating receptors and uses thereof21 Sep 2023US 2023/0293687 A1Eureka Therapeutics, Inc.
Most cited
By later US patents
- Compositions and methods for the therapy and diagnosis of prostate cancer39US 6,800,746 B2Corixa Corporation · 2004
- Recombinant vector expressing multiple costimulatory molecules and uses thereof35US 6,969,609 B1The United States of America as represented by the Department of Health and Human Serivces · 2005
- Recombinant vector expressing multiple costimulatory molecules and uses thereof27US 7,771,715 B2The United States of America as represented by the Department of Health and Human Services · 2010
- Methods of MHC class II epitope mapping, detection of autoimmune T cells and antigens, and autoimmune treatment23US 7,094,555 B2Benaroya Research Institute at Virginia Mason · 2006
- Recombinant vector expressing multiple costimulatory molecules and uses thereof21US 7,211,432 B2The United States of America, as represented by the Secretary, Department of Health and Human Services · 2007